FRANKFURT (dpa-AFX) – Despite a buy recommendation from the British bank HSBC, the shares of Sartorius (Sartorius vz) fell slightly in early trading on Wednesday. They fell by 0.40 percent to 322.40 euros. After the strong run of the past two months, some investors could continue to cash in.
HSBC analyst Rajesh Kumar is positive about the pharmaceutical and laboratory supplier’s growth potential. After a difficult year in 2024, he is also overall more confident about the biotech industry in general.
In 2023, Sartorius – like the entire industry – experienced a reduction in inventory due to customers who had stocked up on too much material during the corona pandemic. With a price loss of around 10 percent, the shares were ultimately among the biggest losers in the DAX (DAX 40), which rose by around a fifth last year.
Nevertheless, Sartorius shares had recovered from their annual low of a good 215 euros in October by more than 60 percent to almost 350 euros by the beginning of January before some investors pocketed profits.
The 21-day line is now in view. This short-term trend indicator is still pointing upwards and is currently just under 330 euros. It could be a hurdle on the way up, but a jump over it could provide further positive impulses.
The shares of the Sartorius subsidiary Sartorius Stedim (Sartorius Stedim Biotech) were up 0.6 percent at EUR 243.60 in the morning. The HSBC expert is also optimistic for Stedim: He raised the price target to 330 euros and classified the shares as “buy”.
Stedim currently has a market value of 22.5 billion euros. For comparison: Sartorius, which holds almost 74 percent of Stedim, has a market capitalization of just under 22 billion euros./mis/ck/men
Selected leverage products on Sartorius vz.
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Sartorius vz.
The leverage must be between 2 and 20
Advertising